Malvern Instruments Acquires NanoSight - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Malvern Instruments Acquires NanoSight



Malvern Instruments, a provider of instrumentation for materials and biophysical characterization, has acquired nanoparticle characterization company NanoSight. The acquisition was completed on Sept. 27, 2013.
 
NanoSight has developed and commercialized Nanoparticle Tracking Analysis (NTA). The company’s instrumentation and software enable multi-parameter analysis and characterization of many different types of nanoscale particles. Nanosight’s ability to analyze particle size, concentration, zeta potential, and aggregation, closely aligns with Malvern’s Zetasizer range, extending Malvern’s solutions for those working at the nanoscale. 
 
NanoSight will continue to operate from its current facilities in Amesbury, Wiltshire, UK, under the existing management team.

Source: NanoSight

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here